| Bioactivity | VR23 is a small molecule that potently inhibits the activities of trypsin-like proteasomes (IC50=1 nM), chymotrypsin-like proteasomes (IC50=50-100 nM), and caspase-like proteasomes (IC50=3 μM). | ||||||||||||
| Invitro | VR23 is a novel proteasome inhibitor targeting β2 of the 20S proteasome subunit. VR23 produces a synergistic effect in killing multiple myeloma cells, including those that were resistant to PS-341. VR23 as a structurally novel proteasome inhibitor with desirable properties as an anticancer agent. | ||||||||||||
| Name | VR23 | ||||||||||||
| CAS | 1624602-30-7 | ||||||||||||
| Formula | C19H16ClN5O6S | ||||||||||||
| Molar Mass | 477.88 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|